
Baxter (BAX) Stock Forecast & Price Target
Baxter (BAX) Analyst Ratings
Bulls say
Baxter International's stock outlook is bolstered by solid growth in its Healthcare Systems & Technologies segment, with recorded sales increases of approximately 6% in 1Q25 and 2% in 2Q25, alongside expectations for continued growth in the latter half of 2025. The positive trajectory is further supported by pricing initiatives projected to yield an additional 100 basis points of sales growth during 2024 and 2025. Expanding its portfolio through the acquisition of Hillrom has diversified Baxter's offerings, allowing for continued innovation and market adaptation amidst evolving healthcare demands.
Bears say
Baxter International's financial performance in the second quarter of 2025 reflected a significant decline, with sales, margins, and earnings per share all falling short of consensus expectations. The company has faced a series of operational challenges from 2021 to 2023, resulting in inconsistent quarterly results and downward guidance revisions. Additionally, a combination of sales softness, manufacturing inefficiencies, and an unfavorable product mix led to gross margins of 40.7%, which missed the consensus of 42.7% and operating margins of 15.1%, falling below consensus by over 100 basis points.
This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.
Baxter (BAX) Analyst Forecast & Price Prediction
Start investing in Baxter (BAX)
Order type
Buy in
Order amount
Est. shares
0 shares